METX Stock Overview
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ME Therapeutics Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$3.96 |
| 52 Week High | CA$7.00 |
| 52 Week Low | CA$0.05 |
| Beta | 0 |
| 1 Month Change | 14.78% |
| 3 Month Change | 227.27% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 546.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| METX | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 2.9% | 3.4% | -0.2% |
| 1Y | n/a | -38.0% | 7.0% |
Return vs Industry: Insufficient data to determine how METX performed against the Canadian Biotechs industry.
Return vs Market: Insufficient data to determine how METX performed against the Canadian Market.
Price Volatility
| METX volatility | |
|---|---|
| METX Average Weekly Movement | 50.5% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CA Market | 18.2% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: METX's share price has been volatile over the past 3 months.
Volatility Over Time: METX's weekly volatility has decreased from 290% to 51% over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Salim Dhanji | www.metherapeutics.com |
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. Its lead candidate is a novel antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. The company was incorporated in 2021 and is headquartered in Vancouver, Canada.
ME Therapeutics Holdings Inc. Fundamentals Summary
| METX fundamental statistics | |
|---|---|
| Market cap | CA$93.59m |
| Earnings (TTM) | CA$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs METX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| METX income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$0 |
| Earnings | CA$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did METX perform over the long term?
See historical performance and comparison